Core Insights - Visteon (VC) is currently rated as a Strong Buy (1) while Ferrari (RACE) holds a Buy (2) rating, indicating a stronger improvement in VC's earnings outlook compared to RACE [3] - Value investors utilize various valuation metrics to assess whether a company is undervalued, including P/E ratio, P/S ratio, earnings yield, and cash flow per share [4] Valuation Metrics - Visteon has a forward P/E ratio of 14.06, significantly lower than Ferrari's forward P/E of 42.88, suggesting that VC may be more attractively priced [5] - The PEG ratio for Visteon is 4.72, while Ferrari's PEG ratio is slightly higher at 4.82, indicating that both companies have similar expected EPS growth rates [5] - Visteon's P/B ratio stands at 2.17, in stark contrast to Ferrari's P/B ratio of 26.85, further highlighting VC's relative undervaluation [6] Value Grades - Visteon has received a Value grade of A, while Ferrari has a Value grade of F, indicating that VC is perceived as a superior value option based on its solid earnings outlook and favorable valuation metrics [6]

Core Viewpoint - Investors in the Leisure and Recreation Products sector should consider Yeti (YETI) as a more attractive option compared to Pool Corp. (POOL) due to its better valuation metrics and earnings outlook [1]. Valuation Metrics - YETI has a forward P/E ratio of 15.11, significantly lower than POOL's forward P/E of 28.01, indicating that YETI may be undervalued [5]. - The PEG ratio for YETI is 2.17, while POOL's PEG ratio is 4.21, suggesting that YETI has a more favorable earnings growth outlook relative to its price [5]. - YETI's P/B ratio stands at 3.29, compared to POOL's P/B of 8.81, further supporting the notion that YETI is undervalued [6]. Analyst Outlook - YETI currently holds a Zacks Rank of 2 (Buy), reflecting a positive earnings estimate revision trend, while POOL has a Zacks Rank of 4 (Sell), indicating a less favorable outlook [3]. - The solid earnings outlook for YETI, combined with its superior valuation metrics, positions it as the better value option in the sector [7].

Core Viewpoint - Puma Biotech (PBYI) has shown strong stock performance, with a 40.6% increase over the past month and a 59% gain since the start of the year, outperforming the Zacks Medical sector and the Zacks Medical - Biomedical and Genetics industry [1] Financial Performance - Puma Biotech has consistently beaten earnings estimates, reporting an EPS of $0.15 against a consensus estimate of $0.11 in its last earnings report [2] - For the current fiscal year, the company is expected to post earnings of $0.65 per share on revenues of $216.32 million, reflecting a -16.67% change in EPS and a -6.15% change in revenues [3] - For the next fiscal year, earnings are projected to be $0.50 per share on revenues of $235.8 million, indicating a year-over-year change of -22.31% in EPS and a 9.01% increase in revenues [3] Valuation Metrics - Puma Biotech has a Value Score of A, with Growth and Momentum Scores of B and C respectively, resulting in a combined VGM Score of A [6] - The stock trades at 7.5X current fiscal year EPS estimates, significantly lower than the peer industry average of 21.2X, and at 5.7X trailing cash flow compared to the peer group's average of 14.9X, positioning it favorably for value investors [7] Zacks Rank - Puma Biotech holds a Zacks Rank of 2 (Buy), supported by a solid earnings estimate revision trend, making it a suitable choice for investors looking for stocks with strong potential [8]

Core Insights - Bunzl PLC (BZLFY) currently presents a better value opportunity compared to Mondelez (MDLZ) based on various financial metrics and rankings [1][3][7] Valuation Metrics - Bunzl PLC has a forward P/E ratio of 12.78, significantly lower than Mondelez's forward P/E of 20.59, indicating that Bunzl may be undervalued [5] - The PEG ratio for Bunzl is 1.18, while Mondelez has a PEG ratio of 4.72, suggesting that Bunzl offers better growth potential relative to its price [5] - Bunzl's P/B ratio stands at 2.83 compared to Mondelez's P/B of 3.08, further supporting the argument that Bunzl is more attractively valued [6] Earnings Estimates - Bunzl holds a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions, while Mondelez has a Zacks Rank of 3 (Hold), suggesting a less favorable outlook [3][7] - The stronger estimate revision activity for Bunzl indicates an improving earnings outlook compared to Mondelez [7]

Core Viewpoint - New York Times Co. (NYT) has shown strong stock performance, with a 3.2% increase over the past month and an 11.8% gain since the start of the year, outperforming both the Zacks Consumer Staples sector and the Zacks Publishing - Newspapers industry [1] Financial Performance - The company has consistently exceeded earnings expectations, reporting an EPS of $0.58 against a consensus estimate of $0.50 in its last earnings report on August 6, 2025 [2] - For the current fiscal year, NYT is projected to achieve earnings of $2.24 per share on revenues of $2.77 billion, reflecting an 11.44% increase in EPS and a 7.08% increase in revenues [3] - The next fiscal year forecasts earnings of $2.40 per share on revenues of $2.95 billion, indicating year-over-year changes of 7.18% and 6.39%, respectively [3] Valuation Metrics - NYT's stock trades at 26 times the current fiscal year EPS estimates, aligning with the peer industry average, while on a trailing cash flow basis, it trades at 22.4 times compared to the peer group's average of 19 times [7] - The stock has a PEG ratio of 1.52, which does not position it among the top value stocks [7] Style Scores and Zacks Rank - NYT has a Value Score of C, with Growth and Momentum Scores rated A, resulting in a combined VGM Score of B [6] - The stock holds a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts [8] - NYT meets the criteria for selection based on Zacks Rank and Style Scores, suggesting potential for further stock price appreciation in the near term [9]

Core Viewpoint - REV Group (REVG) has shown strong stock performance, with a 56.9% increase since the beginning of the year, outperforming the Zacks Transportation sector and the Zacks Transportation - Services industry [1][2]. Financial Performance - REV Group has consistently beaten earnings estimates, reporting EPS of $0.7 against a consensus estimate of $0.59 in its last earnings report [2]. - For the current fiscal year, REV Group is projected to achieve earnings of $2.45 per share on revenues of $2.41 billion, reflecting a 54.09% increase in EPS and a 1.07% increase in revenues [3]. - The next fiscal year forecasts earnings of $3.36 per share on revenues of $2.6 billion, indicating a year-over-year change of 37.01% in EPS and 7.89% in revenues [3]. Valuation Metrics - REV Group has a Value Score of B, a Growth Score of A, and a Momentum Score of F, resulting in a combined VGM Score of B [6]. - The stock trades at 20.4 times the current fiscal year EPS estimates, which is above the peer industry average of 18.8 times [6]. - On a trailing cash flow basis, the stock trades at 26.1 times compared to the peer group's average of 7.5 times, indicating a premium valuation [6]. Zacks Rank - REV Group holds a Zacks Rank of 1 (Strong Buy) due to rising earnings estimates, suggesting potential for further stock price appreciation [7]. - The combination of a Zacks Rank of 1 or 2 and Style Scores of A or B positions REV Group favorably for investors [7].

Core Viewpoint - The comparison between Luxfer (LXFR) and Ingersoll Rand (IR) indicates that LXFR currently offers better value for investors based on various financial metrics and rankings [1][3]. Valuation Metrics - Luxfer has a forward P/E ratio of 11.05, significantly lower than Ingersoll Rand's forward P/E of 23.59 [5]. - The PEG ratio for Luxfer is 1.38, while Ingersoll Rand's PEG ratio is 3.21, suggesting that Luxfer is more reasonably priced relative to its expected earnings growth [5]. - Luxfer's P/B ratio stands at 1.28, compared to Ingersoll Rand's P/B of 3.08, indicating that Luxfer is trading at a lower valuation relative to its book value [6]. Zacks Rank and Style Scores - Luxfer holds a Zacks Rank of 2 (Buy), while Ingersoll Rand has a Zacks Rank of 3 (Hold), suggesting a stronger earnings outlook for Luxfer [3]. - The Style Score Value grade for Luxfer is A, whereas Ingersoll Rand has a Value grade of D, further emphasizing Luxfer's superior valuation metrics [6]. Estimate Revisions - Luxfer has experienced stronger estimate revision activity compared to Ingersoll Rand, making it a more attractive option for value investors [7].

Core Viewpoint - Bancolombia (CIB) and Banco Itau (ITUB) are both considered as potential undervalued stocks in the foreign banking sector, with a focus on their valuation metrics to determine the better investment option [1]. Valuation Metrics - CIB has a forward P/E ratio of 6.81, while ITUB has a forward P/E of 8.60, indicating that CIB may be more undervalued [5]. - The PEG ratio for CIB is 0.96, compared to ITUB's PEG ratio of 0.97, suggesting that both companies have similar expected EPS growth rates [5]. - CIB's P/B ratio is 1.26, while ITUB's P/B ratio is 1.88, further supporting the notion that CIB is the more attractive value option [6]. Earnings Outlook - Both CIB and ITUB currently hold a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions and improving earnings outlooks [3][6]. - CIB has been assigned a Value grade of B, while ITUB has a Value grade of D, highlighting CIB's superior valuation metrics [6].

Core Viewpoint - The comparison between Quanex Building Products (NX) and Holcim Ltd Unsponsored ADR (HCMLY) indicates that NX presents a better value investment opportunity due to its stronger earnings outlook and favorable valuation metrics [1][3][7]. Valuation Metrics - NX has a forward P/E ratio of 7.51, significantly lower than HCMLY's forward P/E of 20.82, suggesting that NX is undervalued relative to HCMLY [5]. - The PEG ratio for NX is 0.54, indicating a more attractive valuation when considering expected earnings growth, while HCMLY's PEG ratio stands at 2.07 [5]. - NX's P/B ratio is 0.9, compared to HCMLY's P/B of 1.44, further supporting the notion that NX is undervalued [6]. Investment Outlook - NX holds a Zacks Rank of 2 (Buy), reflecting an improving earnings estimate revision activity, while HCMLY has a Zacks Rank of 5 (Strong Sell), indicating a less favorable analyst outlook [3][7]. - Based on the combination of its improving earnings outlook and favorable valuation metrics, NX is positioned as the superior value option in the current market [7].

Core Insights - Heidelberg Materials AG Unsponsored ADR (HDLMY) and Advanced Drainage Systems (WMS) are both attractive options for value investors, but a closer examination is necessary to determine which stock is more appealing [1] Valuation Metrics - Both HDLMY and WMS currently hold a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions and improving earnings outlooks for both companies [3] - HDLMY has a forward P/E ratio of 15.23, while WMS has a forward P/E of 20.23, suggesting that HDLMY may be undervalued compared to WMS [5] - The PEG ratio for HDLMY is 1.18, while WMS has a PEG ratio of 1.72, indicating that HDLMY offers better value when considering expected EPS growth [5] - HDLMY's P/B ratio is 2.07, compared to WMS's P/B of 5.98, further supporting the notion that HDLMY is the more attractive value option [6] - Based on these valuation metrics, HDLMY holds a Value grade of B, while WMS has a Value grade of C, reinforcing the conclusion that HDLMY is the superior value option at this time [6]